FSD Pharma Inc. (HUGE) NASDAQ
0.09
-0.0101(-10.10%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.09
-0.0101(-10.10%)
Currency In USD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
17
First IPO Date
June 08, 2018
| Name | Title | Pay | Year Born |
| Lakshmi Kotra | Chief Executive Officer of Lucid & Director | 144,724 | 1971 |
| Zeeshan Saeed | Founder, Chief Executive Officer, President & Executive Co-Chairman | 222,625 | 1970 |
| Andrzej Chruscinski | Vice President of Clinical & Scientific Affairs of Lucid | 110,304 | N/A |
| Kevin Cassidy | Vice President of Quality-Lucid | 144,822 | N/A |
| Nathan Coyle | Chief Financial Officer | 178,208 | 1981 |
| Anthony John Durkacz | Founder & Executive Co-Chairman | 222,625 | 1976 |
| Donal Carroll | Chief Operating Officer | 225,625 | 1977 |
| Maryann Adesso | Corporate Secretary | 0 | N/A |
| Randell Mack | President of FSD BioSciences | 0 | N/A |
FSD Pharma Inc. is a biopharmaceutical research and development company, operating through its various subsidiaries. The firm's leading drug candidate, FSD-201, is currently undergoing Phase II clinical trials for the treatment of COVID-19 disease. Additionally, FSD Pharma is actively developing Lucid-PSYCH, a psychoactive molecule identified for its potential in addressing neuropsychiatric conditions such as depressive disorder. They are also advancing Lucid-MS, a proprietary new chemical entity which, in preclinical models, has demonstrated the capacity to prevent and reverse myelin degradation—the fundamental mechanism behind multiple sclerosis. Established in 1998, FSD Pharma Inc. is headquartered in Toronto, Canada.